| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/30/2014 | WO2014015993A1 Bicyclic aza-amides for treatment of psychiatric disorders |
| 01/30/2014 | WO2014015831A1 Tumor antigenic peptide and application of same as tumor vaccine |
| 01/30/2014 | WO2014015830A1 Novel heteroaryl and heterocycle compounds, composition and methods thereof |
| 01/30/2014 | WO2014015760A1 Crystal form of cabazitaxel and preparation method thereof |
| 01/30/2014 | WO2014015754A1 Broussonetine compound, preparation method therefor, and application thereof |
| 01/30/2014 | WO2014015675A1 Novel heteroaryl and heterocycle compounds, compositions and methods |
| 01/30/2014 | WO2014015673A1 4-position substituted pyrazolopyrimidine derivative, and use thereof in drug preparation |
| 01/30/2014 | WO2014015523A1 Novel heteroaryl and heterocycle compounds, compositions and methods |
| 01/30/2014 | WO2014015422A1 Cellulose-based nanoparticles for drug delivery |
| 01/30/2014 | WO2014003536A9 Dosage regime of fusion compounds |
| 01/30/2014 | WO2013175357A3 Compositions and methods for treatment of inflammatory bowel disease |
| 01/30/2014 | WO2012160223A9 Pharmaceutical composition |
| 01/30/2014 | WO2012158933A9 Macrocycllc therapeutic agents and methods of treatment |
| 01/30/2014 | WO2008019124A8 Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| 01/30/2014 | US20140033335 Immunoglobulin 2 |
| 01/30/2014 | US20140031354 Protein Kinase Inhibitors |
| 01/30/2014 | US20140030319 Antagonists Of The Oncongenic Activity Of The Protein MDM2, And Use Thereof In the Treatment of Cancers |
| 01/30/2014 | US20140030263 Treatment of diffuse large-cell lymphoma with anti-cd20 antibody |
| 01/30/2014 | US20140030251 Composition and method for reducing tissue damage from inflammatory disorder or pathogenic infection |
| 01/30/2014 | CA2874860A1 Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor |
| 01/29/2014 | EP2690175A2 Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression |
| 01/29/2014 | EP2690111A1 Anti-mouse aggrus monoclonal antibody |
| 01/29/2014 | EP2690102A1 Bicyclic aza-amides for treatment of psychiatric disorders |
| 01/29/2014 | EP2690101A1 5-Anilinoimidazopyridines and Methods of Use |
| 01/29/2014 | EP2690096A1 Process for preparation of Bendamustine |
| 01/29/2014 | EP2689779A1 Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| 01/29/2014 | EP2689013A1 Compositions for inhibiting gene expression and uses thereof |
| 01/29/2014 | EP2689010A1 Method and compositions for cellular immunotherapy |
| 01/29/2014 | EP2688904A1 Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy |
| 01/29/2014 | EP2688901A1 INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 |
| 01/29/2014 | EP2688891A1 Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
| 01/29/2014 | EP2688890A1 Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| 01/29/2014 | EP2688888A1 Process for the production of a pemetrexed salt |
| 01/29/2014 | EP2688887A1 Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| 01/29/2014 | EP2688886A1 Azole compounds as pim inhibitors |
| 01/29/2014 | EP2688883A1 Novel pyrimidine derivatives |
| 01/29/2014 | EP2688877A1 Solid state forms of cabazitaxel and processes for preparation thereof |
| 01/29/2014 | EP2688873A1 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
| 01/29/2014 | EP2688872A1 Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| 01/29/2014 | EP2688649A1 Polymorphs of lenalidomide |
| 01/29/2014 | EP2688595A2 Lin28-mediated control of let-7 biogenesis |
| 01/29/2014 | EP2688594A2 Methods and compositions for the treatment of cancer |
| 01/29/2014 | EP2688584A1 Pegylated human hdl particle and process for production thereof |
| 01/29/2014 | EP2688572A1 A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof. |
| 01/29/2014 | EP2688569A1 Treatment of solid tumours |
| 01/29/2014 | EP2688566A2 Anticancer therapeutic agents |
| 01/29/2014 | EP2688565A1 Treatment of proliferative disorders with a chemiluminescent agent |
| 01/29/2014 | EP2688563A1 Gallium complexes, pharmaceutical compositions and methods of use |
| 01/29/2014 | EP2435435B1 Pyrimidine inhibitors of kinase activity |
| 01/29/2014 | EP2078010B1 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 01/29/2014 | EP1196638B1 Use of the krit1 gene in angiogenesis |
| 01/29/2014 | CN103547580A Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| 01/29/2014 | CN103547564A Auto-magnetic metal salen complex compound |
| 01/29/2014 | CN103547315A 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma |
| 01/29/2014 | CN103547284A Immunity inducing agent |
| 01/29/2014 | CN103547279A Lyophilized preparation of cytotoxic dipeptides |
| 01/29/2014 | CN103547278A Immunity induction agent |
| 01/29/2014 | CN103547269A 抗癌剂组合物 Anticancer composition |
| 01/29/2014 | CN103547268A Treatment of solid tumours |
| 01/29/2014 | CN103547263A Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| 01/29/2014 | CN103540655A Application of MK5 gene for screening anti-liver cancer drug |
| 01/29/2014 | CN103540654A Applications of 11-19 lysine-rich leukemia (ELL) gene and expression product thereof |
| 01/29/2014 | CN103540653A Applications of homeobox A1 (HOXA1) gene and expression product thereof |
| 01/29/2014 | CN103540616A Lentiviral vector system for expressing diphtheria toxin A (DTA) fragment as well as preparation method and application thereof |
| 01/29/2014 | CN103540612A Slow virus recombinant plasmid for inhibiting epithelial-mesenchymal transition of breast tumor |
| 01/29/2014 | CN103540591A SiRNA for lowering zinc finger protein A20 expression, and use thereof |
| 01/29/2014 | CN103540498A Wine with antibacterial and antivirus effects, and preparation method thereof |
| 01/29/2014 | CN103539858A Connective tissue growth factor antibodies |
| 01/29/2014 | CN103539851A Generation of artificial binding proteins based on ubiquitin proteins |
| 01/29/2014 | CN103539840A Epidermal growth factor receptor (EGFR) mimotope peptide and application thereof |
| 01/29/2014 | CN103539834A Chemerin derived peptide and expressed gene and application thereof |
| 01/29/2014 | CN103539801A Podophyllotoxin derivative as well as salt, preparation method and application thereof |
| 01/29/2014 | CN103539799A Preparation method and application of water-soluble aminopolycarboxylic acid modified phthalocyanine compound |
| 01/29/2014 | CN103539797A Novel compounds of reverse turn mimetics and the use thereof |
| 01/29/2014 | CN103539793A Thiazole carboxamide compounds and application thereof |
| 01/29/2014 | CN103539785A 大麻素受体调节剂 Cannabinoid receptor modulators |
| 01/29/2014 | CN103539784A Heterocyclic benzamide compounds, pharmaceutical compositions as well as application thereof |
| 01/29/2014 | CN103539783A I-type crystal of dimaleate of tyrosine kinase inhibitor and preparation method thereof |
| 01/29/2014 | CN103539780A Substituted pyrazolone compounds as well as use method and application of substituted pyrazolone compounds |
| 01/29/2014 | CN103539777A PI3 kinase regulator as well as use method and application of PI3 kinase regulator |
| 01/29/2014 | CN103539769A Macrocyclic compounds useful as inhibitors of kinases and HSP90 |
| 01/29/2014 | CN103539760A Phenoxy phenylacetic acid endothelin antagonist, and preparation method and application thereof |
| 01/29/2014 | CN103539735A Crystalline forms of a prolyl hydroxylase inhibitor |
| 01/29/2014 | CN103539722A Aryl-substituted methyl-connected bis-indoleacetic acid derivative and preparation method and application thereof |
| 01/29/2014 | CN103539695A Novel diphenyl ether substituted histone deacetylase inhibitor |
| 01/29/2014 | CN103539659A 2,4-dibenzyloxybenzoic acid derivative and preparation method and application thereof |
| 01/29/2014 | CN103536973A Polyvinyl alcohol magnetic particles as well as preparation method and application thereof |
| 01/29/2014 | CN103536935A Photosensitizer-modified core-shell structure magnetic nanocomposites and preparation method and application thereof |
| 01/29/2014 | CN103536934A Self-assembled nano-gene vector compound based on PAMAM (Poly Amido-Amine) and preparation method thereof |
| 01/29/2014 | CN103536933A New application of siRNA (small interfering ribonucleic acid) of neural differentiation related gene BRSK2 |
| 01/29/2014 | CN103536930A Polylactic acid-polyethylene glycol-tumor penetrating peptide compound, preparation and application thereof |
| 01/29/2014 | CN103536926A Preparation method of chitosan oligosaccharide nanoparticle |
| 01/29/2014 | CN103536925A Application of cardiac glycoside compound in treatment of non-small cell lung cancer |
| 01/29/2014 | CN103536922A Application of acyl-coenzyme A: cholesterol acyltransferase-2 (ACAT2) inhibitor in liver cancer growth inhibition |
| 01/29/2014 | CN103536921A Application of cholesterol metabolite for inhibiting liver cancer growth |
| 01/29/2014 | CN103536920A Pharmaceutical composition for inhibiting pancreatic cancer cell proliferation and application thereof |
| 01/29/2014 | CN103536919A Tumor-targeted photodynamic medicine carrying nanoparticle as well as preparation method and application thereof |
| 01/29/2014 | CN103536918A Phthalocyanine-quantum dot novel photosensitizer and preparation method thereof |
| 01/29/2014 | CN103536917A Use of interferon in treatment of tumor, and related product and method |
| 01/29/2014 | CN103536915A Compositions and methods for the treatment of infections and tumors |